Phaserx Inc.

PhaseRx Inc. is a biotechnology company focused on developing innovative therapies for rare, inherited metabolic disorders, particularly those affecting enzyme function in the liver. Founded in 2006 and headquartered in Seattle, Washington, the company specializes in RNA-based therapeutics and advanced drug delivery systems. PhaseRx is notable for its proprietary polymer-based platform that enables the effective intracellular delivery of RNA interference (RNAi) drugs, facilitating their escape from cellular vesicles to reach therapeutic targets within the cytoplasm. The company’s pipeline has included preclinical and pending candidates designed to address conditions such as citrullinemia, ornithine transcarbamylase deficiency, and argininosuccinic aciduria—diseases that currently have limited treatment options. Through its commitment to rare disease research, PhaseRx has sought to fill critical gaps in the treatment landscape, emphasizing both scientific innovation and translational medicine within the biopharmaceutical sector.